Add like
Add dislike
Add to saved papers

Translation, Cross-cultural Adaptation, and Validation of the Dutch International Hip Outcome Tool-33 (iHOT-33 NL) in Young, Physically Active Individuals With Symptomatic Hip Joint Pathology.

Study Design Prospective cohort. Background The international Hip Outcome Tool-33 (iHOT-33), developed in English, has been shown to be a valid and reliable questionnaire for young, physically active individuals with symptomatic hip joint pathology. Objectives To translate and validate the iHOT-33 in Dutch (iHOT-33 NL) in the target population. Methods Translation and cross-cultural adaptation of the iHOT-33 were performed following existing guidelines. Young to middle-aged (18-50 years), active (Tegner activity score of 3 or greater) individuals presenting with symptomatic hip joint-related pain (numeric pain-rating score of 1 or greater) in a primary health care/hospital setting were included. The iHOT-33 NL, Hip disability and Osteoarthritis Outcome Score (HOOS), European Quality of Life-5 Dimensions questionnaire (EQ-5D), numeric pain-rating score, and Global Perceived Effect score were completed by 214 patients. Results The intraclass correlation coefficient for test-retest reliability was 0.92 (95% confidence interval: 0.88, 0.94). Smallest detectable changes at individual and group levels were, respectively, 16.7 and 1.1 points. The Cronbach alpha was .9. Principal-component analysis revealed 4 domains of the iHOT-33 NL. Of the hypotheses used for construct validity, 87% were confirmed. No floor and ceiling effects were detected for the iHOT-33 NL total score. The minimal important change was 10.7 points. Conclusion The iHOT-33 NL is a reliable and valid patient-reported outcome questionnaire for young, physically active individuals with symptomatic hip joint pathology. It can be used in research and clinical settings. J Orthop Sports Phys Ther 2018;48(4):289-298. doi:10.2519/jospt.2018.7610.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app